Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

about

The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases

P2860

Q26750377-41075580-CAAC-48BE-99AE-AA736CDAA2AE

P2860

Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

Item

http://www.wikidata.org/entity/Q35896444

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@ast

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@en

type

Item

label

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@ast

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@en

prefLabel

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@ast

Apremilast (Otezla): A New Ora ...... iasis and Psoriatic Arthritis.

@en

P1476

Apremilast (Otezla): A New Ora ...... riasis and Psoriatic Arthritis

@en

P2093

Eric Ocheretyaner

http://www.w3.org/2001/XMLSchema#string

Tina Zerilli

http://www.w3.org/2001/XMLSchema#string

P2860

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

P304

495-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26236137

http://www.w3.org/2001/XMLSchema#string

P932

4517531

http://www.w3.org/2001/XMLSchema#string

Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

about

P2860

P2860

Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932